Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer

J Clin Oncol. 2017 Jan;35(1):124-125. doi: 10.1200/JCO.2016.69.7748. Epub 2016 Sep 30.

Authors

Philip W Kantoff¹, James L Gulley¹, Cesar Pico-Navarro¹

Affiliation

¹ Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial

MeSH terms

Biological Therapy*
Cancer Vaccines / therapeutic use*
Disease-Free Survival
Double-Blind Method
Follow-Up Studies
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
Humans
Immunotherapy*
Male
Prostatic Neoplasms, Castration-Resistant / mortality*
Prostatic Neoplasms, Castration-Resistant / therapy*
Reproducibility of Results
Statistics as Topic
Survival Analysis
Treatment Outcome

Substances

Cancer Vaccines
PROSTVAC
Granulocyte-Macrophage Colony-Stimulating Factor

Grants and funding